Association between soy and isoflavone consumption, gastrointestinal (GI) cancer risk
the ONA take:
According to a new study published in the European Journal of Nutrition, soy consumption is only associated with a small decrease in gastrointestinal cancer risk, while isoflavone consumption is significantly associated with a reduction in gastrointestinal cancer risk.
For the study, researchers sought to investigate the association between soy and isoflavone consumption and gastrointestinal cancer risk. Isoflavone is an active soy constituent but can be consumed as a dietary supplement.
Researchers identified 22 case-control and 18 cohort studies with a total participation of 633,476 patients and 13,639 cases of gastrointestinal cancer. Of the 40 studies, 10 were used for a subgroup analysis for isoflavone consumption.
Results showed that there was only a small reduction in gastrointestinal cancer risk due to soy intake (combined odds ratio = 0.93; 95% CI: 0.87 - 0.99; P = 0.01).
Particularly, the association was stronger for colon and colorectal cancers. In contrast, the subgroup analysis for isoflavone showed a significant reduction in gastrointestinal cancer risk, especially colorectal cancer risk, due to isoflavone consumption (OR = 0.73; 95% CI: 0.59 - 0.92; P = 0).
Soy consumption is only associated with a small decrease in gastrointestinal cancer risk.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|